Clinical Trial Update: Study Evaluating Sirolimus in Kidney Transplant Recipients. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating sirolimus in kidney transplant recipients has been completed, with Wyeth (now Pfizer) as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Graft-versus-host Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Kidney Failure, Graft vs Host Disease | Phase 3 | Status: COMPLETED